Compare iShares Global Clean Energy ETF (ICLN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs TG Therapeutics Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.57, while TG Therapeutics Inc trades at $54.14 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | TGTX | |
|---|---|---|
52-Week High | $23.75 | $59.06 |
52-Week Low | $13.41 | $26.39 |
Market Cap | — | $8.26B |
Sector | — | Health |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, is trading at $18.14, down 1.25% on the day, with a bearish technical outlook. The ETF provides exposure to 105 global renewable energy companies but lacks key valuation metrics like P/E and P/S ratios. Recent news highlights strong 2026 performance with over 25% gains, driven by AI-related power demand and global energy security concerns.
The outlook for ICLN is mixed, balancing strong sector tailwinds against policy risks. Investment opportunities include exposure to the growing clean energy transition, while risks involve US permit delays threatening $121 billion in projects and ongoing comparisons showing higher-yielding alternatives. The technical picture suggests near-term pressure with key support at $18.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.
The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
